Skip to search formSkip to main contentSkip to account menu

NOV 002

Known as: NOV-002, NOV002, Oxidized Glutathione NOV-002 
A stabilized formulation of disodium glutathione disulfide (GSSG; oxidized glutathione) and cisplatin (1000:1) with potential chemoprotective and… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Metastasis is the major cause of death in cancer. Most therapies currently in the clinic aim to eradicate primary tumor, but do… 
Highly Cited
2012
Highly Cited
2012
NOV-002 (a formulation of disodium glutathione disulfide) modulates signaling pathways involved in tumor cell proliferation and… 
Review
2011
Review
2011
The vulnerability of some cancer cells to oxidative signals is a therapeutic target for the rational design of new anticancer… 
2010
2010
LBA7007 Background: NOV-002 is a formulation of disodium glutathione disulfide (GSSG). GSSG is a naturally occurring substance… 
2009
2009
CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts Abstract #2141 Background: Chemotherapy induced anemia is a… 
Highly Cited
2008
Highly Cited
2008
NOV-002 is a novel glutathione disulfide mimetic that when administered in combination with standard chemotherapeutic regimens… 
Review
2008
Review
2008
Background: Oxidative signaling to modulate redox-sensitive cell functions is a heretofore unexploited approach to developing new… 
2006
2006
17021 Background: NOV-002 is a proprietary formulation of oxidized glutathione that modulates production of cytokines and…